Min Lee

Min Lee inquired about Phathom Pharmaceuticals' long-term vision beyond Voquezna, including plans to utilize the established GI network for future partnerships and pursue other indications beyond EoE.

Answer

Steven Basta, President and CEO, stated that the only new indication actively pursued for Voquezna is EoE, though other populations (like as-needed use) are being evaluated. He outlined the long-term plan to build a GI company by leveraging the 300-person field force and exploring business development activities for additional commercial or late-stage clinical assets to launch before Voquezna's LOE date (2033/2034).

Min Lee from Guggenheim Partners inquired about Phathom's long-term vision beyond VOQUEZNA, including utilizing the established GI network for future partnerships with commercially ready GI assets or pursuing other indications beyond EoE.

Answer

Steven Basta, President and CEO, stated that EoE is the only new indication actively pursued for VOQUEZNA, though other populations are being evaluated. He confirmed plans to build a leverageable GI base and initiate business development activities to bring in additional commercial or clinical-stage products (Phase II/III) that could launch before VOQUEZNA's LOE date in 2033 or 2034.